|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
80.8 |
220.56 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
366.46
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Long M, Zhou J, Li D, Zheng L, Xu Z, Zhou S. Long-Term Over-Expression of Neuropeptide Y in Hypothalamic Paraventricular Nucleus Contributes to Adipose Tissue Insulin Resistance Partly via the Y5 Receptor. PLoS One. 2015 May 18;10(5):e0126714. doi: 10.1371/journal.pone.0126714. PubMed PMID: 25993471; PubMed Central PMCID: PMC4436377.
2: Sørensen G, Wörtwein G, Fink-Jensen A, Woldbye DP. Neuropeptide Y Y5 receptor antagonism causes faster extinction and attenuates reinstatement in cocaine-induced place preference. Pharmacol Biochem Behav. 2013 Apr;105:151-6. doi: 10.1016/j.pbb.2013.02.010. PubMed PMID: 23454535.
3: Sørensen G, Jensen M, Weikop P, Dencker D, Christiansen SH, Loland CJ, Bengtsen CH, Petersen JH, Fink-Jensen A, Wörtwein G, Woldbye DP. Neuropeptide Y Y5 receptor antagonism attenuates cocaine-induced effects in mice. Psychopharmacology (Berl). 2012 Aug;222(4):565-77. doi: 10.1007/s00213-012-2651-y. PubMed PMID: 22367168.
4: Medeiros PJ, Al-Khazraji BK, Novielli NM, Postovit LM, Chambers AF, Jackson DN. Neuropeptide Y stimulates proliferation and migration in the 4T1 breast cancer cell line. Int J Cancer. 2012 Jul 15;131(2):276-86. doi: 10.1002/ijc.26350. PubMed PMID: 21823118.
5: Schroeder JP, Overstreet DH, Hodge CW. The neuropeptide-Y Y5 receptor antagonist L-152,804 decreases alcohol self-administration in inbred alcohol-preferring (iP) rats. Alcohol. 2005 Jul;36(3):179-86. PubMed PMID: 16377459.
6: Woldbye DP, Nanobashvili A, Sørensen AT, Husum H, Bolwig TG, Sørensen G, Ernfors P, Kokaia M. Differential suppression of seizures via Y2 and Y5 neuropeptide Y receptors. Neurobiol Dis. 2005 Dec;20(3):760-72. PubMed PMID: 15979311.
7: Stratford TR, Wirtshafter D. NPY mediates the feeding elicited by muscimol injections into the nucleus accumbens shell. Neuroreport. 2004 Dec 3;15(17):2673-6. PubMed PMID: 15570176.
8: Schroeder JP, Iller KA, Hodge CW. Neuropeptide-Y Y5 receptors modulate the onset and maintenance of operant ethanol self-administration. Alcohol Clin Exp Res. 2003 Dec;27(12):1912-20. PubMed PMID: 14691378.
9: Silva AP, Carvalho AP, Carvalho CM, Malva JO. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology. 2003 Feb;44(2):282-92. PubMed PMID: 12623227.
10: Kanatani A, Ishihara A, Iwaasa H, Nakamura K, Okamoto O, Hidaka M, Ito J, Fukuroda T, MacNeil DJ, Van der Ploeg LH, Ishii Y, Okabe T, Fukami T, Ihara M. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun. 2000 May 27;272(1):169-73. PubMed PMID: 10872822.
